Tolerance in Heart Transplantation: The Holy Grail, or an Attainable Goal?

Heart Failure Clinics

Volumn 3, Issue 1, 2007, Pages 17-29

  Pierson III, Richard N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; THYMOCYTE ANTIBODY;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIGEN PRESENTATION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; DRUG INHIBITION; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MONOTHERAPY; NONHUMAN; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD28; AUTOANTIGENS; CD40 LIGAND; CHRONIC DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34249673999     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.02.005     Document Type: Review

References (91)

1. Pierson III R.N., Barr M.L., McCullough K.P., et al. SRTR report on the state of transplantation: thoracic organ transplantation. Am J Transplant 4 Suppl 9 (2004) 93-105
2. Edwards L.B., and Keck B.M. Thoracic organ transplantation in the US. Clin Transpl (2002) 29-40
3. Sarwal M., Chua M.S., Kambham N., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349 2 (2003) 125-138
4. Desvaux D., Schwarzinger M., Pastural M., et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation 78 5 (2004) 647-653
5. Pierson III R.N., and Miller G.G. Late graft failure: lessons from clinical and experimental thoracic organ transplantation. Graft 3 2 (2000) 88-93
6. Eisen H., and Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 23 5 Suppl (2004) S207-S213
7. Kobashigawa J.A. Cardiac allograft vasculopathy in heart transplant patients: pathologic and clinical aspects for angioplasty/stenting. J Am Coll Cardiol 48 3 (2006) 462-3
8. Reed E.F., Hong B., Ho E., et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation 61 (1996) 566
9. Itescu S., Tung T.C., Burke E.M., et al. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 352 (1998) 263
10. Azimzadeh A, Pfeiffer S, Wu G, et al. Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms. Transplantation 2006;81(2):255-64.
11. Jurcevic S., Ainsworth M.E., Pomerance A., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 71 7 (2001) 886-892
12. Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates, and is partially regulated by CD154. Am J Transplant. 2005;5(10):2349-59.
13. Uehara S., Chase C.M., Colvin R.B., et al. T-cell depletion eliminates the development of cardiac allograft vasculopathy in mice rendered tolerant by the induction of mixed chimerism. Transplant Proc 38 10 (2006) 3169-3171
14. Kawai T., Cosimi A.B., Wee S.L., et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 73 11 (2002) 1757-1764
15. Calne R.Y. Prope tolerance: the future of organ transplantation-from the laboratory to the clinic. Transplantation 77 6 (2004) 930-932
16. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6 9 (2006) 2121-2133
17. Ildstad S.T., and Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307 5947 (1984) 168-170
18. Ildstad S.T., Wren S.M., Bluestone J.A., et al. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 162 1 (1985) 231-244
19. Chen Z.K., Cobbold S.P., Waldmann H., et al. Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation 62 9 (1996) 1200-1206
20. Utsugi R., Barth R.N., Lee R.S., et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully MHC-mismatched kidney allografts in miniature swine. Transplantation 71 10 (2001) 1368-1379
21. Kawai T., Cosimi A.B., Colvin R.B., et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59 2 (1995) 256-262
22. Starzl T.E., Murase N., Demetris A.J., et al. Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 77 6 (2004) 926-929
23. Zhang T, Vanhove B, Nguyen BH, et al. Efficacy of novel non-activating anti-CD28 scFV antibody in cynomolgus monkey cardiac allotransplantation. American Transplant Congress 2006. Availabe at: http://www.abstracts2view.com/wtc/view.php?nu=WTC06L_545. Accessed April 5, 2007.
24. Han W.R., Murray-Segal L.J., and Mottram P.L. Assessment of peripheral tolerance in anti-CD4 treated C57BL/6 mouse heart transplants recipients. Transpl Immunol 7 1 (1999) 37-44
25. Miller G.G., Davis S.F., Atkinson J.B., et al. Longitudinal analysis of fibroblast growth factor (aFGF) expression after transplantation and association with severity of cardiac allograft vasculopathy. Circulation 100 (1999) 2396-2399
26. Fedoseyeva E.V., Tam R.C., Popov I.A., et al. Induction of T cell responses to a self-antigen following allotransplantation. Transplantation 61 5 (1996) 679-683
27. Fedoseyeva E.V., Fedoseyeva E.V., Kishimoto K., et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 169 3 (2002) 1168-1174
28. Morgun A., Shulzhenko N., Unterkircher C.S., et al. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 23 2 (2004) 204-209
29. Rolls H.K., Kishimoto K., Dong V.M., et al. T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation 74 7 (2002) 1053-1057
30. Fraser J.D., Irving B.A., Crabtree G.R., et al. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251 4991 (1991) 313-316
31. Howland K.C., Ausubel L.J., London C.A., et al. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 164 9 (2000) 4465-4470
32. Williams M.A., Onami T.M., Adams A.B., et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 169 10 (2002) 5387-5391
33. Taylor D.K., Neujahr D., and Turka L.A. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 16 5 (2004) 558-564
34. Baker R.J., Hernandez-Fuentes M.P., Brookes P.A., et al. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 167 12 (2001) 7199-7206
35. Illigens B.M., Yamada A., Fedoseyeva E.V., et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 63 10 (2002) 912-925
36. Quezada S.A., Jarvinen L.Z., Lind E.F., et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
37. Kamradt T., and Mitchison N.A. Tolerance and autoimmunity. N Engl J Med 344 9 (2001) 655-664
38. Wells A.D. T-cell costimulatory pathways relevant to transplant rejection and tolerance. Transplant Rev 16 4 (2002) 205-219
39. Waldmann H., and Cobbold S. Exploiting tolerance processes in transplantation. Science 305 5681 (2004) 209-212
40. Kuwaki K., Tseng Y.L., Dor F.J., et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 11 1 (2005) 29-31
41. Yamada K., Yazawa K., Shimizu A., et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11 1 (2005) 32-34
42. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 16 (1997) 87, 89-94
43. Kirk A.D., Burkly L.C., Batty D.S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5 (1999) 686-693
44. Pierson III R.N., Chang A.C., Blum M.G., et al. Prolongation of primate cardiac allograft survival by treatment with anti-CD40 ligand (CD154) antibody. Transplantation 68 (1999) 1800-1805
45. Pierson III R.N., Crowe Jr. J.E., Pfeiffer S., et al. CD40-ligand in primate cardiac allograft and viral immunity. Immunol Res 23 2-3 (2001) 253-262
46. Montgomery S.P., Xu H., Tadaki D.K., et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 74 10 (2002) 1365-1369
47. Ringers J., Haanstra K.G., Kroczek R.A., et al. Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates. Transplantation 73 6 (2002) 862-866
48. Elster E.A., Xu H., Tadaki D.K., et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation 72 9 (2001) 1473-1478
49. Schuler W., Bigaud M., Brinkmann V., et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77 (2004) 717-726
50. Kenyon N.S., Chatzipetrou M., Masetti M., et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 96 14 (1999) 8132-8137
51. Kirk A.D., Tadaki D.K., Celniker A., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72 3 (2001) 377-384
52. Haanstra K.G., Ringers J., Sick E.A., et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 75 5 (2003) 637-643
53. Pearson T.C., Trambley J., Odom K., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74 (2002) 933-940
54. Adams A.B., Shirasugi N., Durham M.M., et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51 2 (2002) 265-270
55. Boulday G., Bremand L., Karam G., et al. Effect of blockade of the costimulation pathway by anti-B7 antibodies in renal allotransplantation in baboons. Transplant Proc 33 1-2 (2001) 241-242
56. Hausen B., Klupp J., Christians U., et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 72 6 (2001) 1128-1137
57. Birsan T., Hausen B., Higgins J.P., et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 75 12 (2003) 2106-2113
58. Vincenti F., Larsen C., Durrbach A., et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 8 (2005) 770-781
59. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 5 (1994) 405-413
60. Laskowski I.A., Pratschke J., Wilhelm M.J., et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 13 2 (2002) 519-527
61. Wells A.D., Walsh M.C., Bluestone J.A., et al. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 108 6 (2001) 895-903
62. Tang Q., Henriksen K.J., Boden E.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171 7 (2003) 3348-3352
63. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 6581 (1996) 434-438
64. Crowe Jr. J.E., Sannella E.C., Pfeiffer S., et al. CD154 blockade following cardiac allotransplantation inhibits the humoral immune response to influenza vaccine. Am J Transplant 3 6 (2003) 680-688
65. Kawai T., Sogawa H., Boskovic S., et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 4 9 (2004) 1391-1398
66. Noorchashm H., Noorchashm N., Kern J., et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46 6 (1997) 941-946
67. Serreze D.V., Fleming S.A., Chapman H.D., et al. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161 8 (1998) 3912-3918
68. Silveira P.A., Dombrowsky J., Johnson E., et al. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol 172 8 (2004) 5086-5094
69. Noorchashm H., Greeley S.A., and Naji A. The role of T/B lymphocyte collaboration in the regulation of autoimmune and alloimmune responses. Immunol Res 27 2-3 (2003) 443-450
70. Ritchie D.S., Yang J., Hermans I.F., et al. B-lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8 T-cells. Scand J Immunol 60 6 (2004) 543-551
71. Schröder C., Azimzadeh A.M., Wu G., et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunol 12 1 (2003) 19-28
72. Liu C., Velidedeoglu E., Green T., et al. B-lymphocyte directed induction immunotherapy induces long-term islet allograft survival in non-human primates. Am J Transplant 4 S8 (2004)
73. Noorchashm H., Reed A.J., Rostami S.Y., et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 177 11 (2006) 7715-7722
74. Tyden G., Kumlien G., and Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76 4 (2003) 730-731
75. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 4 (2004) 542-548
76. Becker Y.T., Becker B.N., Pirsch J.D., et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4 6 (2004) 996-1001
77. Sonnenday C.J., Warren D.S., Cooper M., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4 8 (2004) 1315-1322
78. Banner N.R., Rose M.L., Cummins D., et al. Management of an ABO-incompatible lung transplant. Am J Transplant 4 7 (2004) 1192-1196
79. Pierson III R.N., Loyd J.E., Goodwin A., et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 74 1 (2002) 79-84
80. Haspot F., Villemain F., Laflamme G., et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 99 6 (2002) 2228-2234
81. Vanhove B., Laflamme G., Coulon F., et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 102 2 (2003) 564-570
82. Matzinger P. An innate sense of danger. Semin Immunol 10 5 (1998) 399-415
83. Tilney N.L., Nadeau K.C., Azuma H., et al. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci U S A 92 19 (1995) 8729-8733
84. Fairchild R.L. Raising the direction signposts that guide T cell trafficking into allografts. Transplantation 79 6 (2005) 646-647
85. Hancock W.W. Chemokine receptor-dependent alloresponses. Immunol Rev 196 (2003) 37-50
86. Schröder C, Pierson III RN, Nguyen BN, et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunology, in press.
87. Kishimoto K., Sandner S., Imitola J., et al. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest 109 11 (2002) 1471-1479
88. Bai Y., Liu J., Wang Y., et al. L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol 168 4 (2002) 1579-1589
89. Lakkis F.G., Arakelov A., Konieczny B.T., et al. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6 6 (2000) 686-688
90. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 5609 (2003) 1033-1036
91. Kishimoto K., Dong V.M., Issazadeh S., et al. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest 106 1 (2000) 63-72